Literature DB >> 16229060

Labeling of cells with ferumoxides-protamine sulfate complexes does not inhibit function or differentiation capacity of hematopoietic or mesenchymal stem cells.

Ali S Arbab1, Gene T Yocum, Ali M Rad, Aarif Y Khakoo, Vicki Fellowes, Elizabeth J Read, Joseph A Frank.   

Abstract

Two FDA-approved agents, ferumoxides (Feridex), a suspension of superparamagnetic iron oxide (SPIO) nanoparticles and protamine sulfate, a drug used to reverse heparin anticoagulation, can be complexed and used to label cells magnetically ex vivo. Labeling stem cells with ferumoxides-protamine sulfate (FePro) complexes allows for non-invasive monitoring by MRI. However, in order for stem cell trials or therapies to be effective, this labeling technique must not inhibit the ability of cells to differentiate. In this study, we examined the effect of FePro labeling on stem cell differentiation. Viability, phenotypic expression and differential capacity of FePro labeled CD34 + hematopoietic stem cells (HSC) and mesenchymal stem cells (MSC) were compared with unlabeled control cells. Colony-forming unit (CFU) assays showed that the capacity to differentiate was equivalent for labeled and unlabeled HSC. Furthermore, labeling did not alter expression of surface phenotypic markers (CD34, CD31, CXCR4, CD20, CD3 and CD14) on HSC, as measured by flow cytometry. SDF-1-induced HSC migration and HSC differentiation to dendritic cells were also unaffected by FePro labeling. Both FePro-labeled and unlabeled MSC were cultured in chondrogenesis-inducing conditions. Alcian blue staining for proteoglycans revealed similar chondrogenic differentiation for both FePro-labeled and unlabeled cells. Furthermore, collagen X proteins, indicators of cartilage formation, were detected at similar levels in both labeled and unlabeled cell pellets. Prussian blue staining confirmed that cells in labeled pellets contained iron oxide, whereas cells in unlabeled pellets did not. It is concluded that FePro labeling does not alter the function or differentiation capacity of HSC and MSC. These data increase confidence that MRI studies of FePro-labeled HSC or MSC will provide an accurate representation of in vivo trafficking of unlabeled cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16229060     DOI: 10.1002/nbm.991

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  100 in total

Review 1.  Advances in cardiovascular molecular imaging for tracking stem cell therapy.

Authors:  Katherine J Ransohoff; Joseph C Wu
Journal:  Thromb Haemost       Date:  2010-05-10       Impact factor: 5.249

2.  In vivo magnetic resonance imaging and optical imaging comparison of viable and nonviable mesenchymal stem cells with a bifunctional label.

Authors:  Elizabeth Jane Sutton; Tobias D Henning; Sophie Boddington; Stavros Demos; Christian Krug; Reinhardt Meier; John Kornak; Shoujun Zhao; Rick Baehner; Sheida Sharifi; Heike Daldrup-Link
Journal:  Mol Imaging       Date:  2010-10       Impact factor: 4.488

Review 3.  Imaging stem cells implanted in infarcted myocardium.

Authors:  Rong Zhou; Paul D Acton; Victor A Ferrari
Journal:  J Am Coll Cardiol       Date:  2006-11-01       Impact factor: 24.094

4.  Visualization of antigen-specific human cytotoxic T lymphocytes labeled with superparamagnetic iron-oxide particles.

Authors:  Ambros J Beer; Konstantin Holzapfel; Juliana Neudorfer; Guido Piontek; Marcus Settles; Holger Krönig; Christian Peschel; Jürgen Schlegel; Ernst J Rummeny; Helga Bernhard
Journal:  Eur Radiol       Date:  2008-02-20       Impact factor: 5.315

Review 5.  Imaging of stem cells using MRI.

Authors:  Dara L Kraitchman; Jeff W M Bulte
Journal:  Basic Res Cardiol       Date:  2008-03       Impact factor: 17.165

6.  Intravenous administration of human umbilical cord blood-derived AC133+ endothelial progenitor cells in rat stroke model reduces infarct volume: magnetic resonance imaging and histological findings.

Authors:  Asm Iskander; Robert A Knight; Zheng Gang Zhang; James R Ewing; Adarsh Shankar; Nadimpalli Ravi S Varma; Hassan Bagher-Ebadian; Meser M Ali; Ali S Arbab; Branislava Janic
Journal:  Stem Cells Transl Med       Date:  2013-08-09       Impact factor: 6.940

7.  The safety and efficacy of magnetic targeting using autologous mesenchymal stem cells for cartilage repair.

Authors:  Naosuke Kamei; Mitsuo Ochi; Nobuo Adachi; Masakazu Ishikawa; Shinobu Yanada; L Scott Levin; Goki Kamei; Takaaki Kobayashi
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2018-03-16       Impact factor: 4.342

8.  Noninvasive monitoring of embryonic stem cells in vivo with MRI transgene reporter.

Authors:  Jun Liu; Eric C H Cheng; Robert C Long; Shang-Hsun Yang; Liya Wang; Pei-Hsun Cheng; Jinjing Yang; Dong Wu; Hui Mao; Anthony W S Chan
Journal:  Tissue Eng Part C Methods       Date:  2009-12       Impact factor: 3.056

9.  Cord blood endothelial progenitor cells as therapeutic and imaging probes.

Authors:  Branislava Janic; Ali S Arbab
Journal:  Imaging Med       Date:  2012-08-01

10.  Ferumoxytol: a new, clinically applicable label for stem-cell tracking in arthritic joints with MRI.

Authors:  Aman Khurana; Hossein Nejadnik; Fanny Chapelin; Olga Lenkov; Rakhee Gawande; Sungmin Lee; Sandeep N Gupta; Nooshin Aflakian; Nikita Derugin; Solomon Messing; Guiting Lin; Tom F Lue; Laura Pisani; Heike E Daldrup-Link
Journal:  Nanomedicine (Lond)       Date:  2013-03-27       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.